Insmed's business model is centered on the high-value, specialty drug market, where a premium price is justified by treating rare diseases with few or no alternative therapies. The company leverages a focused commercial strategy for rare pulmonary and systemic diseases with strong clinical data and regulatory momentum, positioning it for accelerated revenue growth through newly approved and late-stage pipeline assets.
Cyborg Score Rationale
Insmed has demonstrated explosive returns with a stock price surge of over 194% in the last year and market capitalization recently topping $43.41 billion. ARIKAYCE brought in $114.3 million in Q3 2025 with 22% year-over-year growth, while BRINSUPRI contributed $28.1 million in its early U.S. launch phase. The company faces typical biotech profitability challenges but shows strong commercial execution.
Top Insights
BRINSUPRI (brensocatib) European approval in November 2025 represents monumental achievement as first-in-class therapy for non-cystic fibrosis bronchiectasis
ARIKAYCE commands ~$300,000 annualized cost per patient while BRINSUPRI launched with $88,000 yearly list price, supporting premium specialty pricing model
Strong late-stage pipeline with brensocatib in Phase 3 for bronchiectasis and treprostinil palmitil in Phase 3 for pulmonary hypertension associated with interstitial lung disease
24 analysts rate INSM stock as 'Strong Buy' with average 12-month target of $192.27, implying 29% upside from latest price
Named Competitors
Vertex Pharmaceuticals — Cystic fibrosis and rare diseases therapies
Galapagos — Rare disease biopharmaceutical company
Ardelyx — Rare kidney and digestive disease treatments
Recent Developments
(November 2025) BRINSUPRI (brensocatib) approved in European Union as first-in-class therapy for non-cystic fibrosis bronchiectasis
(August 2025) BRINSUPRI FDA approved in United States; strong early commercial uptake with $28.1M Q3 revenue contribution
(Q3 2025) ARIKAYCE delivered $114.3 million in sales, representing 22% year-over-year growth
Open the full interactive Insmed Incorporated report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.